These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 26162577

  • 1. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
    Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM.
    Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
    [Abstract] [Full Text] [Related]

  • 2. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
    Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
    [Abstract] [Full Text] [Related]

  • 3. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [Abstract] [Full Text] [Related]

  • 4. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
    Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Müller M, Brendle C, Werner MK, Claussen CD, Pfannenberg C.
    Cancer Imaging; 2013 Mar 05; 13(1):63-72. PubMed ID: 23466785
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT.
    Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, Lahner H, Führer D, Bockisch A, Herrmann K, Forsting M, Antoch G, Umutlu L.
    Eur Radiol; 2017 Oct 05; 27(10):4091-4099. PubMed ID: 28439648
    [Abstract] [Full Text] [Related]

  • 6. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    Recent Results Cancer Res; 2013 Oct 05; 194():353-71. PubMed ID: 22918768
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U.
    Mol Imaging Biol; 2003 Oct 05; 5(1):42-8. PubMed ID: 14499161
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.
    J Nucl Med; 2014 Feb 05; 55(2):204-10. PubMed ID: 24379222
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report.
    Lee I, Paeng JC, Lee SJ, Shin CS, Jang JY, Cheon GJ, Lee DS, Chung JK, Kang KW.
    Nucl Med Mol Imaging; 2015 Dec 05; 49(4):284-90. PubMed ID: 26550047
    [Abstract] [Full Text] [Related]

  • 11. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M, Kaemmerer D, Prasad V, Hommann M, Baum RP.
    Recent Results Cancer Res; 2013 Dec 05; 194():487-96. PubMed ID: 22918778
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.